{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:40:58Z","timestamp":1775122858640,"version":"3.50.1"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41568-019-0153-5","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T13:02:49Z","timestamp":1560776569000},"page":"392-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":390,"title":["\u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9302","authenticated-orcid":false,"given":"Bruno","family":"Silva-Santos","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-0033","authenticated-orcid":false,"given":"Sofia","family":"Mensurado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-2862","authenticated-orcid":false,"given":"Seth B.","family":"Coffelt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"153_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"153_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"153_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. \u03b3\u03b4 T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"153_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41590-018-0304-y","volume":"20","author":"BE Willcox","year":"2019","unstructured":"Willcox, B. E. & Willcox, C. R. \u03b3\u03b4 TCR ligands: the quest to solve a 500-million-year-old mystery. Nat. Immunol. 20, 121\u2013128 (2019).","journal-title":"Nat. Immunol."},{"key":"153_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcdb.2017.10.009","volume":"84","author":"D Vermijlen","year":"2018","unstructured":"Vermijlen, D., Gatti, D., Kouzeli, A., Rus, T. & Eberl, M. \u03b3\u03b4 T cell responses: how many ligands will it take till we know? Semin. Cell Dev. Biol. 84, 75\u201386 (2018).","journal-title":"Semin. Cell Dev. Biol."},{"key":"153_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","volume":"296","author":"EJ Adams","year":"2015","unstructured":"Adams, E. J., Gu, S. & Luoma, A. M. Human \u03b3 \u03b4 T cells: evolution and ligand recognition. Cell. Immunol. 296, 31\u201340 (2015).","journal-title":"Cell. Immunol."},{"key":"153_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41590-018-0253-5","volume":"19","author":"D Melandri","year":"2018","unstructured":"Melandri, D. et al. The \u03b3\u03b4TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat. Immunol. 19, 1352\u20131365 (2018).","journal-title":"Nat. Immunol."},{"key":"153_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1126\/science.1063916","volume":"294","author":"M Girardi","year":"2001","unstructured":"Girardi, M. et al. Regulation of cutaneous malignancy by \u03b3\u03b4 T cells. Science 294, 605\u2013609 (2001). Seminal work using TCR \u03b4 chain\n                           \u2212\/\u2212 mice to demonstrate a protective role for mouse \u03b3\u03b4 T cells in chemically induced skin cancer.","journal-title":"Science"},{"key":"153_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1084\/jem.20030584","volume":"198","author":"Y Gao","year":"2003","unstructured":"Gao, Y. et al. \u03b3\u03b4 T cells provide an early source of interferon \u03b3 in tumor immunity. J. Exp. Med. 198, 433\u2013442 (2003).","journal-title":"J. Exp. Med."},{"key":"153_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1084\/jem.20031981","volume":"199","author":"SE Street","year":"2004","unstructured":"Street, S. E. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and \u03b3\u03b4 T cells. J. Exp. Med. 199, 879\u2013884 (2004).","journal-title":"J. Exp. Med."},{"key":"153_CR11","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.180.9.6044","volume":"180","author":"Z Liu","year":"2008","unstructured":"Liu, Z. et al. Protective immunosurveillance and therapeutic antitumor activity of \u03b3\u03b4 T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180, 6044\u20136053 (2008).","journal-title":"J. Immunol."},{"key":"153_CR12","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.4049\/jimmunol.1300434","volume":"190","author":"T Lanca","year":"2013","unstructured":"Lanca, T. et al. Protective role of the inflammatory CCR2\/CCL2 chemokine pathway through recruitment of type 1 cytotoxic \u03b3\u03b4 T lymphocytes to tumor beds. J. Immunol. 190, 6673\u20136680 (2013).","journal-title":"J. Immunol."},{"key":"153_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4049\/jimmunol.0903767","volume":"185","author":"W He","year":"2010","unstructured":"He, W. et al. Naturally activated V \u03b3 4 \u03b3 \u03b4 T cells play a protective role in tumor immunity through expression of eomesodermin. J. Immunol. 185, 126\u2013133 (2010).","journal-title":"J. Immunol."},{"key":"153_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","volume":"9","author":"AE Simoes","year":"2018","unstructured":"Simoes, A. E., Di Lorenzo, B. & Silva-Santos, B. Molecular determinants of target cell recognition by human \u03b3\u03b4 T cells. Front. Immunol. 9, 929 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ni1556","volume":"9","author":"J Strid","year":"2008","unstructured":"Strid, J. et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat. Immunol. 9, 146\u2013154 (2008).","journal-title":"Nat. Immunol."},{"key":"153_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1126\/science.1211250","volume":"334","author":"J Strid","year":"2011","unstructured":"Strid, J., Sobolev, O., Zafirova, B., Polic, B. & Hayday, A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 334, 1293\u20131297 (2011).","journal-title":"Science"},{"key":"153_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12080","volume":"7","author":"T Dalessandri","year":"2016","unstructured":"Dalessandri, T., Crawford, G., Hayes, M., Castro Seoane, R. & Strid, J. IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat. Commun. 7, 12080 (2016). A study showing a crucial effect of IL-13-producing \u03b3\u03b4 T cells in maintaining skin integrity and therefore protecting from carcinogenesis.","journal-title":"Nat. Commun."},{"key":"153_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1189\/jlb.5A0116-053RR","volume":"100","author":"G Cao","year":"2016","unstructured":"Cao, G. et al. mTOR inhibition potentiates cytotoxicity of V\u03b34 \u03b3\u03b4 T cells via up-regulating NKG2D and TNF-\u03b1. J. Leukoc. Biol. 100, 1181\u20131189 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"153_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"153_CR20","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","volume":"96","author":"V Groh","year":"1999","unstructured":"Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived \u03b3 \u03b4 T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879\u20136884 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"153_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","volume":"114","author":"Y Kong","year":"2009","unstructured":"Kong, Y. et al. The NKG2D ligand ULBP4 binds to TCR\u03b39\/\u03b42 and induces cytotoxicity to tumor cells through both TCR\u03b3\u03b4 and NKG2D. Blood 114, 310\u2013317 (2009).","journal-title":"Blood"},{"key":"153_CR22","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2009-08-237123","volume":"115","author":"T Lanca","year":"2010","unstructured":"Lanca, T. et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia\/lymphoma susceptibility to \u03b3\u03b4 T cell cytotoxicity. Blood 115, 2407\u20132411 (2010).","journal-title":"Blood"},{"key":"153_CR23","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22892","volume":"2","author":"DV Correia","year":"2013","unstructured":"Correia, D. V., Lopes, A. & Silva-Santos, B. Tumor cell recognition by \u03b3\u03b4 T lymphocytes: T cell receptor versus NK-cell receptors. Oncoimmunology 2, e22892 (2013).","journal-title":"Oncoimmunology"},{"key":"153_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","volume":"174","author":"E Viey","year":"2005","unstructured":"Viey, E. et al. Phosphostim-activated \u03b3 \u03b4 T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338\u20131347 (2005).","journal-title":"J. Immunol."},{"key":"153_CR25","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-07-4912","volume":"14","author":"AA Alexander","year":"2008","unstructured":"Alexander, A. A. et al. Isopentenyl pyrophosphate-activated CD56+ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14, 4232\u20134240 (2008).","journal-title":"Clin. Cancer Res."},{"key":"153_CR26","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.4049\/jimmunol.0804288","volume":"182","author":"M Todaro","year":"2009","unstructured":"Todaro, M. et al. Efficient killing of human colon cancer stem cells by \u03b3\u03b4 T lymphocytes. J. Immunol. 182, 7287\u20137296 (2009).","journal-title":"J. Immunol."},{"key":"153_CR27","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro, M. et al. V\u03b39V\u03b42 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184, 3260\u20133268 (2010).","journal-title":"J. Immunol."},{"key":"153_CR28","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1002\/eji.201243150","volume":"43","author":"P Dokouhaki","year":"2013","unstructured":"Dokouhaki, P. et al. NKG2D regulates production of soluble TRAIL by ex vivo expanded human \u03b3\u03b4 T cells. Eur. J. Immunol. 43, 3175\u20133182 (2013).","journal-title":"Eur. J. Immunol."},{"key":"153_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","volume":"11","author":"Z Li","year":"2011","unstructured":"Li, Z. et al. IFN-\u03b3 enhances HOS and U2OS cell lines susceptibility to \u03b3\u03b4 T cell-mediated killing through the Fas\/Fas ligand pathway. Int. Immunopharmacol. 11, 496\u2013503 (2011).","journal-title":"Int. Immunopharmacol."},{"key":"153_CR30","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1182\/blood-2011-06-363655","volume":"119","author":"L Couzi","year":"2012","unstructured":"Couzi, L. et al. Antibody-dependent anti-cytomegalovirus activity of human \u03b3\u03b4 T cells expressing CD16 (Fc\u03b3RIIIa). Blood 119, 1418\u20131427 (2012).","journal-title":"Blood"},{"key":"153_CR31","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/ijc.23365","volume":"122","author":"H Tokuyama","year":"2008","unstructured":"Tokuyama, H. et al. V\u03b39V\u03b42 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs\u2014rituximab and trastuzumab. Int. J. Cancer 122, 2526\u20132534 (2008).","journal-title":"Int. J. Cancer"},{"key":"153_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","volume":"187","author":"AH Capietto","year":"2011","unstructured":"Capietto, A. H., Martinet, L. & Fournie, J. J. Stimulated \u03b3\u03b4 T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J. Immunol. 187, 1031\u20131038 (2011).","journal-title":"J. Immunol."},{"key":"153_CR33","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","volume":"113","author":"J Gertner-Dardenne","year":"2009","unstructured":"Gertner-Dardenne, J. et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113, 4875\u20134884 (2009).","journal-title":"Blood"},{"key":"153_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","volume":"74","author":"HH Oberg","year":"2014","unstructured":"Oberg, H. H. et al. Novel bispecific antibodies increase \u03b3\u03b4 T cell cytotoxicity against pancreatic cancer cells. Cancer Res. 74, 1349\u20131360 (2014).","journal-title":"Cancer Res."},{"key":"153_CR35","doi-asserted-by":"publisher","first-page":"83392","DOI":"10.18632\/oncotarget.13110","volume":"7","author":"CB Schiller","year":"2016","unstructured":"Schiller, C. B. et al. CD19-specific triplebody SPM-1 engages NK and \u03b3\u03b4 T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget 7, 83392\u201383408 (2016).","journal-title":"Oncotarget"},{"key":"153_CR36","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-13-3464","volume":"20","author":"JP Fisher","year":"2014","unstructured":"Fisher, J. P. et al. Neuroblastoma killing properties of V\u03b42 and V\u03b42-negative \u03b3\u03b4T cells following expansion by artificial antigen-presenting cells. Clin. Cancer Res. 20, 5720\u20135732 (2014).","journal-title":"Clin. Cancer Res."},{"key":"153_CR37","first-page":"10","volume":"9","author":"J Riond","year":"2009","unstructured":"Riond, J., Rodriguez, S., Nicolau, M. L., al Saati, T. & Gairin, J. E. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by \u03b3\u03b4 T and NK cells during the early steps of tumor growth. Cancer Immun. 9, 10 (2009).","journal-title":"Cancer Immun."},{"key":"153_CR38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes, M., Willimann, K. & Moser, B. Professional antigen-presentation function by human \u03b3\u03b4 T Cells. Science 309, 264\u2013268 (2005).","journal-title":"Science"},{"key":"153_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00262-011-1111-6","volume":"61","author":"B Altvater","year":"2012","unstructured":"Altvater, B. et al. Activated human \u03b3\u03b4 T cells induce peptide-specific CD8+ T cell responses to tumor-associated self-antigens. Cancer Immunol. Immunother. 61, 385\u2013396 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"153_CR40","doi-asserted-by":"publisher","first-page":"593562","DOI":"10.1155\/2014\/593562","volume":"2014","author":"C Mao","year":"2014","unstructured":"Mao, C. et al. Tumor-activated TCR\u03b3\u03b4(+) T cells from gastric cancer patients induce the antitumor immune response of TCR\u03b1\u03b2(+) T cells via their antigen-presenting cell-like effects. J. Immunol. Res. 2014, 593562 (2014).","journal-title":"J. Immunol. Res."},{"key":"153_CR41","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1102654","volume":"188","author":"N Himoudi","year":"2012","unstructured":"Himoudi, N. et al. Human \u03b3\u03b4 T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J. Immunol. 188, 1708\u20131716 (2012).","journal-title":"J. Immunol."},{"key":"153_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00262-015-1700-x","volume":"64","author":"M Muto","year":"2015","unstructured":"Muto, M., Baghdadi, M., Maekawa, R., Wada, H. & Seino, K. Myeloid molecular characteristics of human \u03b3\u03b4 T cells support their acquisition of tumor antigen-presenting capacity. Cancer Immunol. Immunother. 64, 941\u2013949 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"153_CR43","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","volume":"116","author":"A Maniar","year":"2010","unstructured":"Maniar, A. et al. Human \u03b3\u03b4 T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116, 1726\u20131733 (2010).","journal-title":"Blood"},{"key":"153_CR44","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1182\/blood-2011-01-328526","volume":"118","author":"O Nussbaumer","year":"2011","unstructured":"Nussbaumer, O., Gruenbacher, G., Gander, H. & Thurnher, M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by \u03b3\u03b4 T lymphocytes. Blood 118, 2743\u20132751 (2011).","journal-title":"Blood"},{"key":"153_CR45","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.183.5.2271","volume":"183","author":"L Wen","year":"1996","unstructured":"Wen, L. et al. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by \u201cnon \u03b1\/\u03b2\u201d T cells. J. Exp. Med. 183, 2271\u20132282 (1996).","journal-title":"J. Exp. Med."},{"key":"153_CR46","first-page":"E39","volume":"112","author":"Y Huang","year":"2015","unstructured":"Huang, Y. et al. \u03b3\u03b4 T cells affect IL-4 production and B cell tolerance. Proc. Natl Acad. Sci. USA 112, E39\u2013E48 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"153_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05487-9","volume":"9","author":"RM Rezende","year":"2018","unstructured":"Rezende, R. M. et al. \u03b3\u03b4 T cells control humoral immune response by inducing T follicular helper cell differentiation. Nat. Commun. 9, 3151 (2018).","journal-title":"Nat. Commun."},{"key":"153_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/eji.201142017","volume":"42","author":"RR Bansal","year":"2012","unstructured":"Bansal, R. R., Mackay, C. R., Moser, B. & Eberl, M. IL-21 enhances the potential of human \u03b3\u03b4 T cells to provide B cell help. Eur. J. Immunol. 42, 110\u2013119 (2012).","journal-title":"Eur. J. Immunol."},{"key":"153_CR49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/intimm\/dxq014","volume":"22","author":"E Shimura","year":"2010","unstructured":"Shimura, E. et al. Epidermal \u03b3\u03b4 T cells sense precancerous cellular dysregulation and initiate immune responses. Int. Immunol. 22, 329\u2013340 (2010).","journal-title":"Int. Immunol."},{"key":"153_CR50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41590-018-0161-8","volume":"19","author":"G Crawford","year":"2018","unstructured":"Crawford, G. et al. Epithelial damage and tissue \u03b3\u03b4 T cells promote a unique tumor-protective IgE response. Nat. Immunol. 19, 859\u2013870 (2018). A work demonstrating that \u03b3\u03b4 T cells provide help for B cells to class-switch to IgE production, resulting in a protective response against tumour development.","journal-title":"Nat. Immunol."},{"key":"153_CR51","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","volume":"71","author":"SR Mattarollo","year":"2011","unstructured":"Mattarollo, S. R. et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809\u20134820 (2011).","journal-title":"Cancer Res."},{"key":"153_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20100269","volume":"208","author":"Y Ma","year":"2011","unstructured":"Ma, Y. et al. Contribution of IL-17-producing \u03b3 \u03b4 T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491\u2013503 (2011).","journal-title":"J. Exp. Med."},{"issue":"6","key":"153_CR53","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1084\/jem.20180660","volume":"216","author":"Benjamin D. Medina","year":"2019","unstructured":"Medina, B. D. et al. Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20180660 (2019).","journal-title":"The Journal of Experimental Medicine"},{"key":"153_CR54","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/eji.200940157","volume":"40","author":"D Wakita","year":"2010","unstructured":"Wakita, D. et al. Tumor-infiltrating IL-17-producing \u03b3\u03b4 T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927\u20131937 (2010).","journal-title":"Eur. J. Immunol."},{"key":"153_CR55","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.4049\/jimmunol.1002901","volume":"186","author":"Y Carmi","year":"2011","unstructured":"Carmi, Y. et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J. Immunol. 186, 3462\u20133471 (2011).","journal-title":"J. Immunol."},{"key":"153_CR56","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-15-0054","volume":"75","author":"L Benevides","year":"2015","unstructured":"Benevides, L. et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 75, 3788\u20133799 (2015).","journal-title":"Cancer Res."},{"key":"153_CR57","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/cas.13005","volume":"107","author":"Y Kimura","year":"2016","unstructured":"Kimura, Y. et al. IL-17A-producing CD30(+) V\u03b41 T cells drive inflammation-induced cancer progression. Cancer Sci. 107, 1206\u20131214 (2016).","journal-title":"Cancer Sci."},{"key":"153_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-15-0154","volume":"4","author":"P Kulig","year":"2016","unstructured":"Kulig, P. et al. IL17A-mediated endothelial breach promotes metastasis formation. Cancer Immunol. Res. 4, 26\u201332 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"153_CR59","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-13-2534","volume":"74","author":"S Ma","year":"2014","unstructured":"Ma, S. et al. IL-17A produced by \u03b3\u03b4 T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74, 1969\u20131982 (2014).","journal-title":"Cancer Res."},{"key":"153_CR60","doi-asserted-by":"publisher","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","volume":"111","author":"M Rei","year":"2014","unstructured":"Rei, M. et al. Murine CD27(-) V\u03b36(+) \u03b3\u03b4 T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, E3562\u2013E3570 (2014). The description of a pro-tumour axis between mouse IL-17-producing \u03b3\u03b4 T cells and pro-inflammatory and pro-angiogenic macrophages in an ovarian cancer mouse model.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"153_CR61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1158\/0008-5472.CAN-17-1416","volume":"78","author":"EC Patin","year":"2018","unstructured":"Patin, E. C. et al. Type I IFN receptor signaling controls IL7-dependent accumulation and activity of protumoral IL17A-producing \u03b3\u03b4T cells in breast cancer. Cancer Res. 78, 195\u2013204 (2018).","journal-title":"Cancer Res."},{"key":"153_CR62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","volume":"25","author":"F McAllister","year":"2014","unstructured":"McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621\u2013637 (2014). A study that shows a pathogenic role for IL-17, provided in the TME by \u03b3\u03b4 T cells and T\n                           H\n                           17 cells, in pancreatic tumour development and progression.","journal-title":"Cancer Cell"},{"key":"153_CR63","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-15-0749","volume":"76","author":"F Housseau","year":"2016","unstructured":"Housseau, F. et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res. 76, 2115\u20132124 (2016).","journal-title":"Cancer Res."},{"key":"153_CR64","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/nm.2015","volume":"15","author":"S Wu","year":"2009","unstructured":"Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15, 1016\u20131022 (2009).","journal-title":"Nat. Med."},{"key":"153_CR65","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015). The study that reveals for the first time a pro-metastatic role for mouse IL-17-producing \u03b3\u03b4 T cells in a breast cancer mouse model.","journal-title":"Nature"},{"key":"153_CR66","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","volume":"197","author":"SE Busch","year":"2016","unstructured":"Busch, S. E. et al. Lung cancer subtypes generate unique immune responses. J. Immunol. 197, 4493\u20134503 (2016).","journal-title":"J. Immunol."},{"key":"153_CR67","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.040","volume":"176","author":"C Jin","year":"2019","unstructured":"Jin, C. et al. Commensal microbiota promote lung cancer development via \u03b3\u03b4 T cells. Cell 176, 998\u20131013 (2019).","journal-title":"Cell"},{"key":"153_CR68","doi-asserted-by":"publisher","first-page":"E9056","DOI":"10.1073\/pnas.1700317114","volume":"114","author":"D Van Hede","year":"2017","unstructured":"Van Hede, D. et al. Human papillomavirus oncoproteins induce a reorganization of epithelial-associated \u03b3\u03b4 T cells promoting tumor formation. Proc. Natl Acad. Sci. USA 114, E9056\u2013E9065 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"153_CR69","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.4049\/jimmunol.1400216","volume":"193","author":"C Gosmann","year":"2014","unstructured":"Gosmann, C., Mattarollo, S. R., Bridge, J. A., Frazer, I. H. & Blumenthal, A. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia. J. Immunol. 193, 2248\u20132257 (2014).","journal-title":"J. Immunol."},{"key":"153_CR70","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.4049\/jimmunol.1000600","volume":"184","author":"KJ Ness-Schwickerath","year":"2010","unstructured":"Ness-Schwickerath, K. J., Jin, C. & Morita, C. T. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human V\u03b32V\u03b42 T cells. J. Immunol. 184, 7268\u20137280 (2010).","journal-title":"J. Immunol."},{"key":"153_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","volume":"118","author":"N Caccamo","year":"2011","unstructured":"Caccamo, N. et al. Differentiation, phenotype, and function of interleukin-17-producing human V\u03b39V\u03b42 T cells. Blood 118, 129\u2013138 (2011).","journal-title":"Blood"},{"key":"153_CR72","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil, R. S. et al. IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int. J. Cancer 139, 869\u2013881 (2016).","journal-title":"Int. J. Cancer"},{"key":"153_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2014.11.009","volume":"27","author":"MR Rutkowski","year":"2015","unstructured":"Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 27\u201340 (2015).","journal-title":"Cancer Cell"},{"key":"153_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","volume":"40","author":"P Wu","year":"2014","unstructured":"Wu, P. et al. \u03b3\u03b4 T 17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785\u2013800 (2014). \u03b3\u03b4T The first report of a pro-tumour role for human IL-17-producing \u03b3\u03b4 T cells in colorectal cancer.","journal-title":"Immunity"},{"key":"153_CR75","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1347742","volume":"6","author":"S Meraviglia","year":"2017","unstructured":"Meraviglia, S. et al. Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).","journal-title":"Oncoimmunology"},{"key":"153_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14381","volume":"8","author":"J Kargl","year":"2017","unstructured":"Kargl, J. et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat. Commun. 8, 14381 (2017).","journal-title":"Nat. Commun."},{"key":"153_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/2326-6066.CIR-16-0348","volume":"5","author":"E Lo Presti","year":"2017","unstructured":"Lo Presti, E. et al. Squamous cell tumors recruit \u03b3\u03b4 T cells producing either IL17 or IFN\u03b3 depending on the tumor stage. Cancer Immunol. Res. 5, 397\u2013407 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"153_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1850","volume":"212","author":"D Wesch","year":"2001","unstructured":"Wesch, D., Glatzel, A. & Kabelitz, D. Differentiation of resting human peripheral blood \u03b3 \u03b4 T cells toward Th1\u2212 or Th2-phenotype. Cell. Immunol. 212, 110\u2013117 (2001).","journal-title":"Cell. Immunol."},{"key":"153_CR79","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.4049\/jimmunol.1101389","volume":"187","author":"J Hao","year":"2011","unstructured":"Hao, J. et al. Regulatory role of V\u03b31 \u03b3\u03b4 T cells in tumor immunity through IL-4 production. J. Immunol. 187, 4979\u20134986 (2011).","journal-title":"J. Immunol."},{"key":"153_CR80","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/cmi.2015.07","volume":"13","author":"Y Mao","year":"2016","unstructured":"Mao, Y. et al. A new effect of IL-4 on human \u03b3\u03b4 T cells: promoting regulatory V\u03b41 T cells via IL-10 production and inhibiting function of V\u03b42 T cells. Cell. Mol. Immunol. 13, 217\u2013228 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"153_CR81","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.4049\/jimmunol.1701172","volume":"199","author":"V Sundblad","year":"2017","unstructured":"Sundblad, V., Morosi, L. G., Geffner, J. R. & Rabinovich, G. A. Galectin-1: a jack-of-all-trades in the resolution of acute and chronic inflammation. J. Immunol. 199, 3721\u20133730 (2017).","journal-title":"J. Immunol."},{"key":"153_CR82","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","volume":"166","author":"D Daley","year":"2016","unstructured":"Daley, D. et al. \u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation. Cell 166, 1485\u20131499 (2016).","journal-title":"Cell"},{"key":"153_CR83","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","volume":"6","author":"AJ Gunderson","year":"2016","unstructured":"Gunderson, A. J. et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270\u2013285 (2016).","journal-title":"Cancer Discov."},{"key":"153_CR84","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/2326-6066.CIR-17-0655","volume":"6","author":"N Khosravi","year":"2018","unstructured":"Khosravi, N. et al. IL22 promotes Kras-mutant lung cancer by induction of a protumor immune response and protection of stemness properties. Cancer Immunol. Res. 6, 788\u2013797 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"153_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15632","volume":"8","author":"DR McKenzie","year":"2017","unstructured":"McKenzie, D. R. et al. IL-17-producing \u03b3\u03b4 T cells switch migratory patterns between resting and activated states. Nat. Commun. 8, 15632 (2017).","journal-title":"Nat. Commun."},{"key":"153_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1334744","volume":"6","author":"K Kersten","year":"2017","unstructured":"Kersten, K. et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1\u03b2 in tumor-associated macrophages. Oncoimmunology 6, e1334744 (2017).","journal-title":"Oncoimmunology"},{"key":"153_CR87","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.4049\/jimmunol.168.10.4920","volume":"168","author":"A Glatzel","year":"2002","unstructured":"Glatzel, A. et al. Patterns of chemokine receptor expression on peripheral blood \u03b3 \u03b4 T lymphocytes: strong expression of CCR5 is a selective feature of V \u03b4 2\/V \u03b3 9 \u03b3 \u03b4 T cells. J. Immunol. 168, 4920\u20134929 (2002).","journal-title":"J. Immunol."},{"key":"153_CR88","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1158\/0008-5472.CAN-13-0348","volume":"73","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Specific recruitment of \u03b3\u03b4 regulatory T cells in human breast cancer. Cancer Res. 73, 6137\u20136148 (2013).","journal-title":"Cancer Res."},{"key":"153_CR89","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","volume":"192","author":"JC Ribot","year":"2014","unstructured":"Ribot, J. C., Ribeiro, S. T., Correia, D. V., Sousa, A. E. & Silva-Santos, B. Human \u03b3\u03b4 thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling. J. Immunol. 192, 2237\u20132243 (2014).","journal-title":"J. Immunol."},{"key":"153_CR90","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","volume":"118","author":"DV Correia","year":"2011","unstructured":"Correia, D. V. et al. Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992\u20131001 (2011).","journal-title":"Blood"},{"key":"153_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s002620050509","volume":"47","author":"T Yamaguchi","year":"1998","unstructured":"Yamaguchi, T. et al. Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood \u03b3\u03b4T cells isolated from glioblastoma patients. Cancer Immunol. Immunother. 47, 97\u2013103 (1998).","journal-title":"Cancer Immunol. Immunother."},{"key":"153_CR92","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fimmu.2018.00658","volume":"9","author":"HH Van Acker","year":"2018","unstructured":"Van Acker, H. H. et al. Interleukin-15-cultured dendritic cells enhance anti-tumor \u03b3 \u03b4 T cell functions through IL-15 secretion. Front. Immunol. 9, 658 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR93","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1002\/eji.200939922","volume":"39","author":"JD Haas","year":"2009","unstructured":"Haas, J. D. et al. CCR6 and NK1.1 distinguish between IL-17A and IFN-\u03b3-producing \u03b3\u03b4 effector T cells. Eur. J. Immunol. 39, 3488\u20133497 (2009).","journal-title":"Eur. J. Immunol."},{"key":"153_CR94","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/CJI.0b013e3181c80ffa","volume":"33","author":"W Li","year":"2010","unstructured":"Li, W. et al. Effect of IL-18 on expansion of \u03b3\u03b4 T cells stimulated by zoledronate and IL-2. J. Immunother. 33, 287\u2013296 (2010).","journal-title":"J. Immunother."},{"key":"153_CR95","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.4049\/jimmunol.0803068","volume":"182","author":"A Thedrez","year":"2009","unstructured":"Thedrez, A. et al. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V \u03b3 9V \u03b4 2 T cells for adoptive immunotherapy. J. Immunol. 182, 3423\u20133431 (2009).","journal-title":"J. Immunol."},{"key":"153_CR96","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ccell.2015.07.014","volume":"28","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. IL-36\u03b3 transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses. Cancer Cell 28, 296\u2013306 (2015).","journal-title":"Cancer Cell"},{"key":"153_CR97","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jhep.2012.12.015","volume":"58","author":"Y Yi","year":"2013","unstructured":"Yi, Y. et al. The functional impairment of HCC-infiltrating \u03b3\u03b4 T cells, partially mediated by regulatory T cells in a TGF\u03b2- and IL-10-dependent manner. J. Hepatol. 58, 977\u2013983 (2013).","journal-title":"J. Hepatol."},{"key":"153_CR98","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fimmu.2018.01271","volume":"9","author":"A Sacchi","year":"2018","unstructured":"Sacchi, A. et al. Myeloid-derived suppressor cells specifically suppress IFN-\u03b3 production and antitumor cytotoxic activity of V\u03b42 T cells. Front. Immunol. 9, 1271 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR99","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/eji.201343664","volume":"44","author":"F Sabbione","year":"2014","unstructured":"Sabbione, F. et al. Neutrophils suppress \u03b3\u03b4 T cell function. Eur. J. Immunol. 44, 819\u2013830 (2014).","journal-title":"Eur. J. Immunol."},{"key":"153_CR100","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41388-018-0627-z","volume":"38","author":"L Li","year":"2018","unstructured":"Li, L. et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral \u03b3\u03b4 T cell equilibrium via tumor-derived exosomes. Oncogene 38, 2830\u20132843 (2018).","journal-title":"Oncogene"},{"key":"153_CR101","doi-asserted-by":"publisher","first-page":"1554175","DOI":"10.1080\/2162402X.2018.1554175","volume":"8","author":"C Rossi","year":"2019","unstructured":"Rossi, C. et al. Boosting \u03b3\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology 8, 1554175 (2019).","journal-title":"Oncoimmunology"},{"key":"153_CR102","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/eji.201040959","volume":"41","author":"M Iwasaki","year":"2011","unstructured":"Iwasaki, M. et al. Expression and function of PD-1 in human \u03b3\u03b4 T cells that recognize phosphoantigens. Eur. J. Immunol. 41, 345\u2013355 (2011).","journal-title":"Eur. J. Immunol."},{"key":"153_CR103","doi-asserted-by":"publisher","first-page":"1550618","DOI":"10.1080\/2162402X.2018.1550618","volume":"8","author":"T Hoeres","year":"2019","unstructured":"Hoeres, T., Holzmann, E., Smetak, M., Birkmann, J. & Wilhelm, M. PD-1 signaling modulates interferon-\u03b3 production by Gamma Delta (\u03b3\u03b4) T-Cells in response to leukemia. Oncoimmunology 8, 1550618 (2019).","journal-title":"Oncoimmunology"},{"key":"153_CR104","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3389\/fimmu.2018.01367","volume":"9","author":"GM Siegers","year":"2018","unstructured":"Siegers, G. M., Dutta, I., Lai, R. & Postovit, L. M. Functional plasticity of \u03b3 \u03b4 T cells and breast tumor targets in hypoxia. Front. Immunol. 9, 1367 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR105","first-page":"448","volume":"6","author":"NV Rodrigues","year":"2018","unstructured":"Rodrigues, N. V. et al. Low-density lipoprotein uptake inhibits the activation and antitumor functions of human V\u03b39V\u03b42 T cells. Cancer. Immunol. Res. 6, 448\u2013457 (2018).","journal-title":"Immunol. Res."},{"key":"153_CR106","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","volume":"56","author":"SR Mattarollo","year":"2007","unstructured":"Mattarollo, S. R., Kenna, T., Nieda, M. & Nicol, A. J. Chemotherapy and zoledronate sensitize solid tumour cells to V\u03b39V\u03b42 T cell cytotoxicity. Cancer Immunol. Immunother. 56, 1285\u20131297 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"153_CR107","doi-asserted-by":"publisher","DOI":"10.4161\/onci.25821","volume":"2","author":"M Todaro","year":"2013","unstructured":"Todaro, M., Meraviglia, S., Caccamo, N., Stassi, G. & Dieli, F. Combining conventional chemotherapy and \u03b3\u03b4 T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology 2, e25821 (2013).","journal-title":"Oncoimmunology"},{"key":"153_CR108","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3389\/fimmu.2018.01239","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Decitabine enhances V\u03b39V\u03b42 T cell-mediated cytotoxic effects on osteosarcoma cells via the NKG2DL-NKG2D axis. Front. Immunol. 9, 1239 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR109","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fimmu.2018.00617","volume":"9","author":"C Niu","year":"2018","unstructured":"Niu, C. et al. Decitabine inhibits \u03b3 \u03b4 T cell cytotoxicity by promoting KIR2DL2\/3 expression. Front. Immunol. 9, 617 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR110","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3389\/fimmu.2018.01615","volume":"9","author":"SA Bhat","year":"2018","unstructured":"Bhat, S. A., Vedpathak, D. M. & Chiplunkar, S. V. Checkpoint blockade rescues the repressive effect of histone deacetylases inhibitors on \u03b3\u03b4 T cell function. Front. Immunol. 9, 1615 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR111","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.aah3648","volume":"359","author":"CM Dejea","year":"2018","unstructured":"Dejea, C. M. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359, 592\u2013597 (2018).","journal-title":"Science"},{"key":"153_CR112","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833\u20131842 (2017).","journal-title":"Lancet"},{"key":"153_CR113","doi-asserted-by":"publisher","first-page":"17549","DOI":"10.1073\/pnas.1204327109","volume":"109","author":"ML Michel","year":"2012","unstructured":"Michel, M. L. et al. Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing \u03b3\u03b4 cells. Proc. Natl Acad. Sci. USA 109, 17549\u201317554 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"153_CR114","first-page":"713859","volume":"2013","author":"Q Tang","year":"2013","unstructured":"Tang, Q. et al. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm. 2013, 713859 (2013).","journal-title":"Mediators Inflamm."},{"key":"153_CR115","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1484979","volume":"7","author":"L Douguet","year":"2018","unstructured":"Douguet, L. et al. Inflammation drives nitric oxide synthase 2 expression by \u03b3\u03b4 T cells and affects the balance between melanoma and vitiligo associated melanoma. Oncoimmunology 7, e1484979 (2018).","journal-title":"Oncoimmunology"},{"key":"153_CR116","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1208878","volume":"5","author":"L Douguet","year":"2016","unstructured":"Douguet, L. et al. Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of \u03b3\u03b417 T cells in melanoma. Oncoimmunology 5, e1208878 (2016).","journal-title":"Oncoimmunology"},{"key":"153_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00910-z","volume":"8","author":"AE Baek","year":"2017","unstructured":"Baek, A. E. et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat. Commun. 8, 864 (2017).","journal-title":"Nat. Commun."},{"key":"153_CR118","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/ni.3488","volume":"17","author":"M Kathania","year":"2016","unstructured":"Kathania, M. et al. Itch inhibits IL-17-mediated colon inflammation and tumorigenesis by ROR-\u03b3t ubiquitination. Nat. Immunol. 17, 997\u20131004 (2016).","journal-title":"Nat. Immunol."},{"key":"153_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2004990","volume":"16","author":"S Mensurado","year":"2018","unstructured":"Mensurado, S. et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ \u03b3\u03b4 T cells through induction of oxidative stress. PLOS Biol. 16, e2004990 (2018).","journal-title":"PLOS Biol."},{"key":"153_CR120","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1061175","volume":"5","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology 5, e1061175 (2016).","journal-title":"Oncoimmunology"},{"key":"153_CR121","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/bjo.83.9.1069","volume":"83","author":"AA Bialasiewicz","year":"1999","unstructured":"Bialasiewicz, A. A., Ma, J. X. & Richard, G. Alpha\/\u03b2- and \u03b3\/\u03b4 TCR(+) lymphocyte infiltration in necrotising choroidal melanomas. Br. J. Ophthalmol. 83, 1069\u20131073 (1999).","journal-title":"Br. J. Ophthalmol."},{"key":"153_CR122","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"153_CR123","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini, M. et al. Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017).","journal-title":"Oncoimmunology"},{"key":"153_CR124","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/eji.200939222","volume":"39","author":"DL Gibbons","year":"2009","unstructured":"Gibbons, D. L. et al. Neonates harbour highly active \u03b3\u03b4 T cells with selective impairments in preterm infants. Eur. J. Immunol. 39, 1794\u20131806 (2009).","journal-title":"Eur. J. Immunol."},{"key":"153_CR125","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng, G. et al. Tumor-infiltrating \u03b3\u03b4 T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27, 334\u2013348 (2007).","journal-title":"Immunity"},{"key":"153_CR126","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.4049\/jimmunol.1201892","volume":"189","author":"C Ma","year":"2012","unstructured":"Ma, C. et al. Tumor-infiltrating \u03b3\u03b4 T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029\u20135036 (2012).","journal-title":"J. Immunol."},{"key":"153_CR127","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.4049\/jimmunol.1202369","volume":"190","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Tumor-derived \u03b3\u03b4 regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 190, 2403\u20132414 (2013).","journal-title":"J. Immunol."},{"key":"153_CR128","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","volume":"102","author":"M Wilhelm","year":"2003","unstructured":"Wilhelm, M. et al. \u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200\u2013206 (2003). A pioneering clinical trial showing the safety and efficacy of in vivo V\u03b39V\u03b42 T cell activation in patients with lymphoma.","journal-title":"Blood"},{"key":"153_CR129","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using \u03b3-\u03b4 T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469\u2013476 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"153_CR130","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bjc.2011.293","volume":"105","author":"AJ Nicol","year":"2011","unstructured":"Nicol, A. J. et al. Clinical evaluation of autologous \u03b3\u03b4 T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 105, 778\u2013786 (2011).","journal-title":"Br. J. Cancer"},{"key":"153_CR131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/cmi.2012.39","volume":"10","author":"JJ Fournie","year":"2013","unstructured":"Fournie, J. J. et al. What lessons can be learned from \u03b3\u03b4 T cell-based cancer immunotherapy trials? Cell. Mol. Immunol. 10, 35\u201341 (2013). A review providing an insightful discussion of the limited success of cancer clinical trials based on V\u03b39V\u03b42 T cells.","journal-title":"Cell. Mol. Immunol."},{"key":"153_CR132","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2016.06.001","volume":"64","author":"K Wistuba-Hamprecht","year":"2016","unstructured":"Wistuba-Hamprecht, K. et al. Proportions of blood-borne V\u03b41+ and V\u03b42+ T cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur. J. Cancer 64, 116\u2013126 (2016).","journal-title":"Eur. J. Cancer"},{"key":"153_CR133","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cell.2018.11.003","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1443 (2018).","journal-title":"Cell"},{"key":"153_CR134","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","volume":"132","author":"I de Weerdt","year":"2018","unstructured":"de Weerdt, I. et al. Improving CLL V\u03b39V\u03b42-T cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood 132, 2260\u20132272 (2018).","journal-title":"Blood"},{"key":"153_CR135","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375641","volume":"7","author":"RCG de Bruin","year":"2017","unstructured":"de Bruin, R. C. G. et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells. Oncoimmunology 7, e1375641 (2017).","journal-title":"Oncoimmunology"},{"key":"153_CR136","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3389\/fimmu.2018.00814","volume":"9","author":"HH Oberg","year":"2018","unstructured":"Oberg, H. H. et al. Tribody [(HER2)2xCD16] is more effective than trastuzumab in enhancing \u03b3\u03b4 T cell and natural killer cell cytotoxicity against HER2-expressing cancer cells. Front. Immunol. 9, 814 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR137","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","volume":"120","author":"C Grunder","year":"2012","unstructured":"Grunder, C. et al. \u03b39 and \u03b42CDR3 domains regulate functional avidity of T cells harboring \u03b39\u03b42TCRs. Blood 120, 5153\u20135162 (2012).","journal-title":"Blood"},{"key":"153_CR138","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marcu-Malina","year":"2011","unstructured":"Marcu-Malina, V. et al. Redirecting \u03b1\u03b2 T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor. Blood 118, 50\u201359 (2011). A work that establishes a proof of principle for transferring V\u03b39V\u03b42 TCRs into \u03b1\u03b2 T cells to improve their antitumour efficacy and safety.","journal-title":"Blood"},{"key":"153_CR139","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans, T. et al. GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR. Front. Immunol. 9, 1062 (2018).","journal-title":"Front. Immunol."},{"key":"153_CR140","unstructured":"Netherlands Trial Register. Trial NL6357 (NTR6541). TrialRegister.nl https:\/\/www.trialregister.nl\/trial\/6357 (2017)."},{"key":"153_CR141","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cell.2016.08.030","volume":"167","author":"R Di Marco Barros","year":"2016","unstructured":"Di Marco Barros, R. et al. Epithelia use butyrophilin-like molecules to shape organ-specific \u03b3\u03b4 T cell compartments. Cell 167, 203\u2013218 (2016).","journal-title":"Cell"},{"key":"153_CR142","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. \u03b41 T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795\u20135804 (2016). A study providing preclinical proof of principle for an application of V\u03b41\n                           + cells in adoptive immunotherapy of CLL.","journal-title":"Clin. Cancer Res."},{"key":"153_CR143","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal \u03b4 one T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"153_CR144","doi-asserted-by":"publisher","first-page":"eaav4036","DOI":"10.1126\/sciimmunol.aav4036","volume":"3","author":"PM Benveniste","year":"2018","unstructured":"Benveniste, P. M. et al. Generation and molecular recognition of melanoma-associated antigen-specific human \u03b3\u03b4 T cells. Sci. Immunol. 3, eaav4036 (2018).","journal-title":"Sci. Immunol."},{"key":"153_CR145","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.canlet.2016.07.001","volume":"380","author":"HR Mirzaei","year":"2016","unstructured":"Mirzaei, H. R., Mirzaei, H., Lee, S. Y., Hadjati, J. & Till, B. G. Prospects for chimeric antigen receptor (CAR) \u03b3\u03b4 T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 380, 413\u2013423 (2016).","journal-title":"Cancer Lett."},{"key":"153_CR146","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","volume":"126","author":"M Rischer","year":"2004","unstructured":"Rischer, M. et al. Human \u03b3\u03b4 T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br. J. Haematol. 126, 583\u2013592 (2004).","journal-title":"Br. J. Haematol."},{"key":"153_CR147","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","volume":"21","author":"DC Deniger","year":"2013","unstructured":"Deniger, D. C. et al. Bispecific T cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T cell receptors and introduced CD19-specific chimeric antigen receptor. Mol. Ther. 21, 638\u2013647 (2013).","journal-title":"Mol. Ther."},{"key":"153_CR148","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","volume":"131","author":"AI Salter","year":"2018","unstructured":"Salter, A. I., Pont, M. J. & Riddell, S. R. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131, 2621\u20132629 (2018).","journal-title":"Blood"},{"key":"153_CR149","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"153_CR150","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a\u00a0single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"153_CR151","doi-asserted-by":"publisher","first-page":"93179","DOI":"10.1172\/jci.insight.93179","volume":"2","author":"NA Zumwalde","year":"2017","unstructured":"Zumwalde, N. A. et al. Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight 2, 93179 (2017).","journal-title":"JCI Insight"},{"key":"153_CR152","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1168554","volume":"5","author":"U Jarry","year":"2016","unstructured":"Jarry, U. et al. Stereotaxic administrations of allogeneic human V\u03b39V\u03b42 T cells efficiently control the development of human glioblastoma brain tumors. Oncoimmunology 5, e1168554 (2016).","journal-title":"Oncoimmunology"},{"key":"153_CR153","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","volume":"20","author":"DC Deniger","year":"2014","unstructured":"Deniger, D. C. et al. Activating and propagating polyclonal \u03b3\u03b4 T cells with broad specificity for malignancies. Clin. Cancer Res. 20, 5708\u20135719 (2014).","journal-title":"Clin. Cancer Res."},{"key":"153_CR154","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.4049\/jimmunol.1602019","volume":"198","author":"A Qaqish","year":"2017","unstructured":"Qaqish, A. et al. Adoptive transfer of phosphoantigen-specific \u03b3\u03b4 T cell subset attenuates Mycobacterium tuberculosis infection in nonhuman primates. J. Immunol. 198, 4753\u20134763 (2017).","journal-title":"J. Immunol."},{"key":"153_CR155","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","volume":"175","author":"H Sicard","year":"2005","unstructured":"Sicard, H. et al. In vivo immunomanipulation of V\u03b39V\u03b42 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175, 5471\u20135480 (2005).","journal-title":"J. Immunol."},{"key":"153_CR156","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder, K. T. et al. Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751\u2013757 (2007). An important paper showing that upon stem cell transplantation, efficient V\u03b41\n                           + T cell reconstitution is associated with improved clinical outcomes in patients with leukaemia.","journal-title":"Bone Marrow Transplant."},{"key":"153_CR157","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","volume":"125","author":"I Airoldi","year":"2015","unstructured":"Airoldi, I. et al. \u03b3\u03b4 T cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-\u03b1\u03b2+\/CD19+ lymphocytes. Blood 125, 2349\u20132358 (2015).","journal-title":"Blood"},{"key":"153_CR158","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16\u201325 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"153_CR159","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"153_CR160","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-13-2462","volume":"74","author":"M Cheng","year":"2014","unstructured":"Cheng, M. et al. Microbiota modulate tumoral immune surveillance in lung through a \u03b3\u03b4T17 immune cell-dependent mechanism. Cancer Res. 74, 4030\u20134041 (2014).","journal-title":"Cancer Res."},{"key":"153_CR161","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.it.2017.01.007","volume":"38","author":"M Munoz-Ruiz","year":"2017","unstructured":"Munoz-Ruiz, M., Sumaria, N., Pennington, D. J. & Silva-Santos, B. Thymic determinants of \u03b3\u03b4 T cell differentiation. Trends Immunol. 38, 336\u2013344 (2017).","journal-title":"Trends Immunol."},{"key":"153_CR162","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrclinonc.2009.169","volume":"6","author":"C Tripodo","year":"2009","unstructured":"Tripodo, C. et al. Gamma-\u03b4 T cell lymphomas. Nat. Rev. Clin. Oncol. 6, 707\u2013717 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"153_CR163","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/ejh.12439","volume":"94","author":"M Foppoli","year":"2015","unstructured":"Foppoli, M. & Ferreri, A. J. Gamma-\u03b4 t-cell lymphomas. Eur. J. Haematol. 94, 206\u2013218 (2015).","journal-title":"Eur. J. Haematol."},{"key":"153_CR164","first-page":"264","volume":"90","author":"DM Matos","year":"2005","unstructured":"Matos, D. M., Rizzatti, E. G., Fernandes, M., Buccheri, V. & Falcao, R. P. \u03b3\u03b4 and \u03b1\u03b2 T cell acute lymphoblastic leukemia: comparison of their clinical and immunophenotypic features. Haematologica 90, 264\u2013266 (2005).","journal-title":"Haematologica"},{"key":"153_CR165","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/leu.2016.363","volume":"31","author":"ST Ribeiro","year":"2017","unstructured":"Ribeiro, S. T. et al. Casein kinase 2 controls the survival of normal thymic and leukemic \u03b3\u03b4 T cells via promotion of AKT signaling. Leukemia 31, 1603\u20131610 (2017).","journal-title":"Leukemia"},{"key":"153_CR166","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/309757a0","volume":"309","author":"H Saito","year":"1984","unstructured":"Saito, H. et al. Complete primary structure of a heterodimeric T cell receptor deduced from cDNA sequences. Nature 309, 757\u2013762 (1984).","journal-title":"Nature"},{"key":"153_CR167","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/322145a0","volume":"322","author":"MB Brenner","year":"1986","unstructured":"Brenner, M. B. et al. Identification of a putative second T cell receptor. Nature 322, 145\u2013149 (1986).","journal-title":"Nature"},{"key":"153_CR168","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/322179a0","volume":"322","author":"I Bank","year":"1986","unstructured":"Bank, I. et al. A functional T3 molecule associated with a novel heterodimer on the surface of immature human thymocytes. Nature 322, 179\u2013181 (1986).","journal-title":"Nature"},{"key":"153_CR169","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/325683a0","volume":"325","author":"J Borst","year":"1987","unstructured":"Borst, J. et al. A T cell receptor \u03b3\/CD3 complex found on cloned functional lymphocytes. Nature 325, 683\u2013688 (1987).","journal-title":"Nature"},{"key":"153_CR170","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0923-2494(96)89648-9","volume":"147","author":"JJ Fournie","year":"1996","unstructured":"Fournie, J. J. & Bonneville, M. Stimulation of \u03b3\u03b4 T cells by phosphoantigens. Res. Immunol. 147, 338\u2013347 (1996).","journal-title":"Res. Immunol."},{"key":"153_CR171","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly, C. et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T cell subset. Blood 120, 2269\u20132279 (2012). A seminal paper on butyrophilin subfamily 3 member A1 and its role in inducing cellular stress-sensing by human V\u03b39V\u03b42 T cells.","journal-title":"Blood"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-019-0153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-019-0153-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-019-0153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T08:19:52Z","timestamp":1650442792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-019-0153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":171,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1038\/s41568-019-0153-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736003602.793573522","asserted-by":"object"}]},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"17 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S.-S. is a co-founder and shareholder of Lymphact, the company that developed DOT cells, which was acquired in 2018 by GammaDelta Therapeutics (London, UK). S.M. and S.B.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}